Lupin Wins FDA Approval for Generic Dapagliflozin Metformin Diabetes Tablets

Lupin Limited received U.S. Food and Drug Administration approval for its abbreviated new drug application covering dapagliflozin and metformin hydrochloride extended-release tablets in multiple strengths, opening a new competitive front in the American generic diabetes drug market.

The India-headquartered pharmaceutical company announced the clearance on April 8, 2026, positioning it to market a lower-cost version of a widely prescribed combination used to manage type 2 diabetes. Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor, a class that works through a kidney-based mechanism distinct from metformin, which has been a cornerstone of diabetes care for decades. Together, the two drugs offer complementary blood sugar control, and dapagliflozin carries additional evidence of cardiovascular and renal benefits in certain patient groups, giving the combination clinical weight beyond glycemic management alone.

The approval targets a meaningful commercial opportunity. Type 2 diabetes affects tens of millions of Americans, and branded combination therapies carry prices that strain patients, insurers, and public payers alike. Generic entry typically compresses list prices, and health plans often shift such drugs to preferred formulary tiers where patient cost-sharing is lower. For people who rely on dapagliflozin-metformin combinations daily, that formulary placement can translate directly into what they pay at the pharmacy counter each month.

Lupin framed the approval as part of its deliberate push to expand volume and margin in its U.S. generics business. The clearance covers multiple tablet strengths, mirroring the full range of branded products currently on the market and allowing Lupin to compete across the prescribing spectrum rather than in a narrow dosage niche.

The competitive impact will ultimately depend on how many other generic manufacturers receive similar approvals and on contracting arrangements with pharmacy benefit managers. Multiple entrants into a generic class historically produce sharper price compression than single-entrant markets. Lupin said it plans to move toward commercialization promptly, pending final labeling and distribution arrangements.